Quanterix price target raised to $32 from $30 at Scotiabank

Scotiabank raised the firm’s price target on Quanterix (QTRX) to $32 from $30 and keeps an Outperform rating on the shares. The company’s Q4 results were consistent with its preannouncement made back in January and its initial 2024 revenue guidance exceeded prior expectations, the analyst tells investors. Looking ahead, the company’s most important and impactful strategy objective for the year is the advancement of the blood-based Alzheimer’s disease diagnostics, the firm adds. The FDA approval of Eli Lilly’s (LLY) donanemab and the Quanterix’s FDA submission of the p-Tau 217 IVD assay will be important catalysts, Scotiabank says.